life scienc diagnost tool
buy rais pt
reiter buy rais pt report
anoth except quarter yesterday broad-bas strength across
geographi custom type busi segment includ
organ revenu growth ep growth full year guidanc
rais top bottom line despit increment
less favor fx environ notabl organ revenu
growth guidanc rate seen sinc
much differ smaller compani littl pick term
recent execut three quarter row high singl digit organ
revenu growth ep growth without storm cloud
horizon believ investor focu may shift toward growth
sustain tougher comparison next year beyond first
overal life scienc tool lst industri dont anticip
current better weve seen recent past end market dynam
last indefinit continu believ compel long-term
growth precis medicin etc sustain continu
support lsd msd growth industri specif
largest compani industri unparallel commerci
scale tmo abil compet innov underappreci
view look ahead believ compani better posit
ever capit fastest grow segment lst
market benefit recent strateg invest achiev least
compar better growth vs smaller competitor valuat
assum in-lin price-to-earnings multipl vs peer group
model updat revenu ep estim
y/i vs prior y/i vs
prior revenu ep estim
y/i factor currenc headwind vs billion
prior y/i vs prior
valuat pt base price-to-earnings
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit varianc million except per share data
actualstreet estimate btig chang profit gross margin incom oper margin rate incom chang
exhibit end market observ growth constant currenc
hsd msd year
msd msd year
low-teen year
china grew high-teen
low-teen msd year
y/i growth hsd year
strong growth across tmo busi
particularli bioproduct clinic
outlook msd hsd growth
hsd growth msd year
strong demand mass spectrometri
outlook lsd msd growth
hsd growth lsd year
strength season busi good
demand biomark test
outlook lsd msd growth
msd growth msd year
continu good growth chemic analysi
outlook msd growth
mid-teen
high-teen growth china
msd
y/i growth
continu strength across busi serv
growth china
continu strength across busi
grew msd
modest growth north america good growth
strength across geographi saw increas
europ china
flow fund
grew lsd
grew hsd
strength across analyt instrument
busi serv custom base
continu strength analyt instrument busi
revenu growth full year
strong growth across board particularli
strong growth bioproduct bioscienc
adj om bp expans y/i strong
bioproduct bioscienc
full year adj om expans bp
product volum pull-through favor fx
partial off-set unfavor mix strateg
revenu growth full year
strong growth across busi
full year adj om expans bp
strong growth across busi electron
adj om bp expans y/i strong
volum leverag product partial off-set
strateg invest dilut impact fx
revenu growth full year
strong growth season product good
strong growth healthcar market channel
adj om bp declin y/i strong
product off-set mix strateg invest
good growth across busi includ next-
gen sequenc bioproduct bioscienc
adj om bp y/i strong volum pull-
good product favor fx partial
off-set strateg invest
good growth across busi includ
chemic analysi chromatography/mass spec
adj om bp y/i strong product
volum leverag partial off-set strateg
strong growth transplant diagnost clinic
diagnost healthcar market channel
adj om flat y/i good volum leverag
favor fx off-set strateg invest
servic
perform clinic transplant
full year adj om declin bp
larg attribut unfavor mix
revenu growth full year
strong growth across busi
includ patheon acquisit
particularli channel busi clinic
full year adj om declin bp
larg attribut unfavor mix
strong growth clinic trial logist research
strong growth across busi led clinic
adj om bp declin y/i strong volum
leverag product off-set mix strateg
trial logist research safeti market channel
adj om bp y/i slight accret
acquisit good volum leverag off-set
busi mix strateg invest
tailwind
includ bp dilut patheon
vs
fx tailwind
increas midpoint vs prior
increas midpoint vs prior
increas midpoint vs prior
total tailwind
bp expans exclud impact
million
larg driven new pension account
adopt net impact adj ep
due time discret plan item
rate slightli lower slightli
higher remain quarter year
increment increas midpoint
incl increas strong
oper perform increas
favor fx environ fx tailwind
dilut
share
million assum share
buyback complet
still share buyback
y/i increas due time
project full year patheon impact
dividend increas
quarterli cash dividend
quarterli phase
increas midpoint vs prior
growth higher vs
increas midpoint vs prior
due patheon
benefit total tailwind
net incom
increment increas
stronger op perf due
total fx tail wind
tariff impact
buy-back ye
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
